Flourishglobal Peptide Biotech: difference between revisions
Diff·revision 13 → 14·08:05, 25 Apr 2025
Difference between revision 13 and revision 14 of Flourishglobal Peptide Biotech. 5 lines changed; the page grew by 535 bytes.
| Revision 13 — 08:41, 18 Apr 2025 NPOV_Nadia (talk) British spelling per PP:MOS 4,883 bytes +33 | Revision 14 — 08:05, 25 Apr 2025 UnderfillUna (talk) promote subsection to section 5,418 bytes +535 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. | 2 | | name = Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. |
| + | 3 | | image = facility.svg | |
| + | 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| 3 | | Legal name = Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. | 5 | | Legal name = Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. |
| 4 | | Trading name = FGP | 6 | | Trading name = FGP |
| ⋮ | ⋮ | ||
| 28 | Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.{{r|reports}} That is a more considered [[Cold chain|cold-chain]] arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg. | 30 | Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.{{r|reports}} That is a more considered [[Cold chain|cold-chain]] arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg. |
| 29 | 31 | ||
| + | 32 | Certificates in submitted material have reported purity and appearance; water figures have appeared on some and not others, which suggests the practice is not standardised.{{r|reports,usp1503}} | |
| + | 33 | ||
| 30 | == References == | 34 | == References == |
| 31 | {{reflist}} | 35 | {{reflist}} |
| ⋮ | ⋮ | ||
| 34 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 38 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 35 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 39 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 36 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 41 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 37 | 42 |